Skip to content
Calculator
Evidence: MediumPeptidomimeticNot FDA ApprovedTRH analogueApproved in Japan 2000 · CeredistSpinocerebellar degeneration

Taltirelin

An oral form of the brain hormone TRH, approved in Japan for a rare movement disorder

Taltirelin is a modified thyrotropin-releasing hormone that works by mouth and lasts longer than TRH. Approved in Japan since 2000 as Ceredist for ataxia in spinocerebellar degeneration, it is not approved in the US or EU.

Used in human trials: 5 mg, Twice daily, Oral (Trial: ataxia in spinocerebellar degeneration) Details ↓

Overview

What is it?

Thyrotropin-releasing hormone (TRH) is a three-amino-acid brain hormone best known for telling the pituitary to release thyroid-stimulating hormone. It also acts as a messenger within the brain, which is why researchers have looked for forms of it that reach the brain and last longer. Spinocerebellar degeneration, the condition taltirelin is approved for in Japan, is a group of disorders that cause progressive loss of coordination.

Taltirelin is a modified TRH designed to survive being taken by mouth and to act more on the brain than on the thyroid. According to a 2001 drug profile, it was approved in Japan in July 2000 and launched that September as Ceredist, the first oral drug for spinocerebellar degeneration. In a small study of people after stroke, eight weeks of daily oral doses left thyroid and pituitary hormones within the normal range.

The best modern trial is Korean: in 149 patients with ataxia, 24 weeks of taltirelin slowed worsening on an ataxia rating scale slightly compared with controls. Animal studies have explored it as a breathing stimulant against opioid-induced respiratory depression and as an anti-itch agent, but there are no human data for those uses.

Most of what explains taltirelin comes from animals and cells, and it should be read that way. At the human receptor it binds less tightly than TRH but drives a bigger maximal signal, a superagonist profile. In rats it kept its effect over two weeks of dosing where TRH faded, and it raised dopamine gently in a Parkinson's model without the dyskinesia L-DOPA can cause. In rodents it also reversed morphine's suppression of breathing, sped recovery after massive blood loss, eased inflammatory pain through descending noradrenaline and serotonin pathways, restored running in models of cancer fatigue, and eased PTSD-like behaviour after severe stress.

None of those uses has been tested in people. The human evidence is the ataxia indication, small studies of speech and of thyroid safety after stroke, and the 24-week Korean trial at 5 mg twice daily, whose benefit on the rating scale was modest. A sleep apnoea angle is the newest: applied to the brainstem nucleus that drives the tongue, it raised tongue muscle activity in sleeping mice.

5 mg
Twice daily in the 24-week trial
149 patients with ataxia · PMID 39428104
2000
Approved in Japan
Ceredist, spinocerebellar degeneration · PMID 15931571
Superagonist
At the human TRH receptor
cell study
Science

Mechanism of Action

Taltirelin is a modified thyrotropin-releasing hormone that survives oral dosing. It activates the TRH type 1 receptor in the brain, with a larger maximal response than TRH itself and, in animal studies, stronger central and weaker thyroid effects.

🧠

Central TRH receptors

Superagonist at the human TRH receptor in cells; acts mainly through TRH-R1 in mice.

🚶

Movement and dopamine

Raises dopamine steadily and improves movement in rodent models of ataxia and Parkinson's disease.

🫁

Breathing and circulation

Reversed opioid breathing depression and haemorrhagic shock in rats.

🩹

Pain

Eases inflammatory pain in mice through descending noradrenaline and serotonin pathways.

Evidence

Published Research

The studies behind taltirelin, read from their PubMed abstracts.

Review2001

Approval in Japan

A drug profile records that a new drug application was filed in Japan in April 1999 for spinocerebellar degeneration, approved in July 2000, and launched in September 2000 as the first orally administered drug for the condition.

PMID: 15931571
Human2024

Korean trial in ataxia, 149 patients

Patients randomised to taltirelin 5 mg twice daily or control for 24 weeks; the ataxia score changed by -0.51 on taltirelin against +0.36 on control (p = 0.032), with gains in stance and speech, but no significant differences in the other secondary outcomes.

PMID: 39428104
Human2003

Speech in Machado-Joseph disease

In 10 patients, four weeks of taltirelin made the timing of repeated syllables more regular on acoustic analysis, more so in milder cases, while the overall ataxia rating did not change significantly.

PMID: 12884823
Human1993

Thyroid axis after stroke

In people after stroke given 2.5 to 20 mg by mouth daily for eight weeks, thyroid hormones and TSH stayed within normal ranges and the TSH response to TRH was not significantly changed.

PMID: 8142670
Review2022

A possible opioid-breathing reversal agent

A review of 52 papers found TRH and taltirelin stimulated breathing in animals given opioids, but intravenous TRH did not reverse opioid-induced respiratory depression in humans, and no human data exist for taltirelin.

PMID: 35621218
Animal2024

Itch in mice

Taltirelin reduced scratching after a chemical itch trigger in a dose-dependent way and eased a model of chronic itch in mice.

PMID: 39603612
In Vitro2012

A superagonist at the human receptor

In cells carrying the human TRH receptor, taltirelin bound less tightly and signalled less potently than TRH, yet produced a larger maximal response, making it a superagonist. The authors suggest this may help explain its stronger effects on the brain in people.

PMID: 23087672
Animal2005

No tolerance with repeated dosing

In rats given two weeks of treatment, repeated TRH lost much of its effect on movement and reduced TRH receptor binding in the brain, while taltirelin at an equally stimulating dose kept its effect and left receptor binding unchanged.

PMID: 16368129
Animal2018

Parkinson's model in rats

In rats with one-sided dopamine lesions, 1 to 10 mg/kg taltirelin by injection improved movement for 7 days without causing dyskinesia; it released dopamine gently and steadily, where L-DOPA caused a sharp spike.

PMID: 30555300
In Vitro2018

Protecting dopamine neurons

In cultured human neuroblastoma cells and rat midbrain neurons exposed to the toxins MPP+ or rotenone, taltirelin at 5 µM reduced reactive oxygen species and cell death; the study also reports protection in mouse models of Parkinson's disease.

PMID: 30618632
Animal2018

Reversing opioid breathing depression in rats

In anaesthetised rats given morphine, intravenous taltirelin at 1 mg/kg raised ventilation from 45% to 168% of baseline, mainly by speeding breathing, and reversed the morphine-induced fall in blood oxygen, which TRH did not.

PMID: 29674333
Animal2011

Blood loss in rats

After massive bleeding in anaesthetised rats, intravenous taltirelin at 0.03 to 0.3 mg/kg sped recovery of blood pressure and breathing and prolonged survival in a dose-dependent way, more potently than TRH, through central muscarinic pathways.

PMID: 22044177
Animal2011

Persistent inflammatory pain in mice

In mice with inflamed paws, 1 mg/kg taltirelin markedly reduced touch-evoked pain; depleting noradrenaline or serotonin, or blocking alpha-2 or 5-HT1A receptors, removed the effect, pointing to descending pain-control pathways.

PMID: 21872219
Animal2017

Cancer-related fatigue in mice

In mouse models of chemotherapy, radiation and tumour-related fatigue, taltirelin restored treadmill running distance, an effect that depended on the TRH type 1 receptor.

PMID: 28720519
Animal2026

PTSD-like behaviour in mice

After a prolonged stress procedure that lowered TRH and its receptor in the hippocampus, taltirelin treatment eased PTSD-like behaviour in male mice and restored neural oscillations.

PMID: 41330489
Animal2023

Tongue muscle activity in sleeping mice

Delivered directly to the hypoglossal motor nucleus, taltirelin raised tongue muscle activity in sleeping mice, a lead for obstructive sleep apnoea, where pharyngeal muscle tone matters.

PMID: 37516800
Dosing

Dosing Data

Taltirelin is approved in Japan (Ceredist). The doses below are from published human studies; we have not read the Japanese label itself.

These are study doses. Taltirelin is not approved in the US or EU, and its Japanese approval is for spinocerebellar degeneration only. See a doctor first.
ProtocolDoseFrequencyDurationRoute
Trial: ataxia in spinocerebellar degeneration Human studyPMID 394281045 mgTwice daily24 weeksOral
Study: thyroid safety after stroke Human studyPMID 81426702.5 to 20 mgDaily8 weeksOral

Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.

Study doses
The Korean ataxia trial used 5 mg by mouth twice daily for 24 weeks; a stroke study used 2.5 to 20 mg daily for eight weeks.
Open Calculator →
For Buyers

What a Buyer Needs to Know

What is sold, how it is mixed, stored and taken, and what is known about its safety, quality and legal status. Each part names its source. Where we have none, it says unknown.

What is sold

Unknown: we hold no label and no published test that says what forms or vial sizes Taltirelin is sold in. A vial's own label is a seller's claim, not a source.

Mixing a vial: a worked example

No worked example: none of the doses on this page is a fixed amount in mg or mcg injected under the skin or into a muscle (the routes given are: oral). There is no home-mixing step to show. The reconstitution calculator does the arithmetic for any vial.

Source: the route and amount of each dose row in Dosing Data below.

Storage before and after mixing

Unknown: no label or published stability study on file says how to store Taltirelin, before or after mixing. The mixing guide sets out the general rules, with their sources: keep a mixed vial in the fridge, and use it promptly, as the bacteriostatic water label says of any drug dissolved in it. The 28 days often quoted is the limit for an opened multiple-dose vial from a manufacturer, an outer limit set for sterility, not a time a mixed solution has been shown to keep. Nobody has published how long Taltirelin stays intact once mixed.

How it is taken

As it was given in human studies: Oral (Twice daily; Trial: ataxia in spinocerebellar degeneration).

For injection technique, sites and needle disposal, see the mixing guide.

Source: Used in human trials: the route and frequency of each row in Dosing Data below.

What to expect, and when

How long it stays in the body: not established by a measurement cited on this entry.

How long the doses were given: Trial: ataxia in spinocerebellar degeneration: 24 weeks; Study: thyroid safety after stroke: 8 weeks.

When effects appear: unknown; no source on this page gives a time to effect for Taltirelin. Results reported in the studies are under Published Research.

Source: Used in human trials, the duration of each row in Dosing Data below.

Side effects, and when to stop or get help

From the Side Effects section: Thyroid hormones stayed within normal ranges over eight weeks after stroke; The trials summarised here report no major safety concerns, but their abstracts give little adverse-event detail. Full list and cautions ↓

When to stop or get help: unknown; no label or trial on file sets rules for stopping Taltirelin. Treat a severe or unexpected reaction as a reason to stop and see a doctor.

Source: the Side Effects section below (“From the studies above”).

Interactions

Unknown: a PubMed search for human interaction studies of Taltirelin (reviewed 2026-10-05) found none. Unknown is not the same as safe to combine.

Every peptide's record, with its source: the interaction matrix.

Checking what you bought

Unknown: no published independent test of Taltirelin products is in our lab-results database yet, so how products sold under this name measure up is not known.

To read a certificate of analysis, paste it into the COA decoder; it checks the measured mass against Taltirelin's expected mass, 405.4 Da, from this entry's molecular data. Trust & Verification explains what independent testing can and cannot show.

Legal status

US: Not FDA Approved (Approved in Japan in July 2000 and launched in September 2000 as Ceredist (Tanabe Seiyaku) for spinocerebellar degeneration, according to a 2001 drug profile (PMID 15931571)). Sport: Unsettled (S0 may apply).

Country by country ↓ · Regulatory tracker

Source: this entry's approval status and the WADA Prohibited List, as in Legal Status below.

Safety

Side Effects & Contraindications

Reported Side Effects

From the studies above.

● Thyroid hormones stayed within normal ranges over eight weeks after stroke
● The trials summarised here report no major safety concerns, but their abstracts give little adverse-event detail

Contraindications & Cautions

Taltirelin has no US label. Points from the research.

● Not approved in the US or EU: no US labelled dose, warnings or interactions exist
● It acts on TRH receptors, which also govern thyroid hormone release
● Tested athletes — see the Sport (WADA) row below
Questions

Frequently Asked Questions

?What is taltirelin?

An orally active analogue of thyrotropin-releasing hormone, approved in Japan in 2000 as Ceredist for ataxia in spinocerebellar degeneration.

?Does taltirelin work for ataxia?

In a 24-week Korean trial of 149 patients, it slowed worsening on an ataxia scale slightly compared with controls, with gains in stance and speech but not in other measures.

?Is taltirelin approved in the US?

No. Drugs@FDA holds no record for it, and it has no central EU authorisation.

?What dose of taltirelin was used in trials?

The 24-week Korean trial in ataxia used 5 mg by mouth twice daily. An earlier study in people after stroke used 2.5 to 20 mg daily for eight weeks and found thyroid hormones stayed normal.

?Could taltirelin reverse opioid overdose?

Only animal data exist. In anaesthetised rats it reversed morphine's suppression of breathing and oxygen levels, but it has not been tested for this in people.

Bibliography

References

  1. [fda] US FDA, Drugs@FDA (openFDA): no application for taltirelin. Read October 3, 2026.
  2. [pubmed] Brown WM. "Taltirelin (Tanabe Seiyaku)." IDrugs, 2001;4(12):1389-400. PMID: 15931571.
  3. [clinical-trial] Cho JW, et al. "Efficacy and Safety of Taltirelin Hydrate in Patients With Ataxia Due to Spinocerebellar Degeneration." J Mov Disord, 2025;18(1):35-44. PMID: 39428104.
  4. [clinical-trial] Shirasaki H, et al. "[A quantitative evaluation of spinocerebellar degeneration by an acoustic analysis--the effect of taltirelin hydrate on patients with Machado-Joseph disease]." Rinsho Shinkeigaku, 2003;43(4):143-8. PMID: 12884823.
  5. [pubmed] Miyashita K, et al. "Alteration by prolonged oral administration of a thyrotropin-releasing hormone analog, TA-0910, of the pituitary-thyroid axis in subjects with brain stroke." Intern Med, 1993;32(9):681-5. PMID: 8142670.
  6. [pubmed] Algera MH, et al. "Are thyrotropin-releasing hormone (TRH) and analog taltirelin viable reversal agents of opioid-induced respiratory depression?." Pharmacol Res Perspect, 2022;10(3):e00974. PMID: 35621218.
  7. [pubmed] Eto K, et al. "Thyrotropin-Releasing Hormone Analog Taltirelin Inhibits Acute and Chronic Itch in Mice." Biol Pharm Bull, 2024;47(11):1927-1930. PMID: 39603612.
  8. [pubmed] Thirunarayanan N, et al. "Taltirelin is a superagonist at the human thyrotropin-releasing hormone receptor." Front Endocrinol (Lausanne), 2012;3:120. PMID: 23087672.
  9. [pubmed] Asai H, et al. "Lack of behavioral tolerance by repeated treatment with taltirelin hydrate, a thyrotropin-releasing hormone analog, in rats." Pharmacol Biochem Behav, 2005;82(4):646-51. PMID: 16368129.
  10. [pubmed] Zheng C, et al. "TRH Analog, Taltirelin Improves Motor Function of Hemi-PD Rats Without Inducing Dyskinesia via Sustained Dopamine Stimulating Effect." Front Cell Neurosci, 2018;12:417. PMID: 30555300.
  11. [pubmed] Zheng C, et al. "TRH Analog, Taltirelin Protects Dopaminergic Neurons From Neurotoxicity of MPTP and Rotenone." Front Cell Neurosci, 2018;12:485. PMID: 30618632.
  12. [pubmed] Boghosian JD, et al. "Intravenous and Intratracheal Thyrotropin Releasing Hormone and Its Analog Taltirelin Reverse Opioid-Induced Respiratory Depression in Isoflurane Anesthetized Rats." J Pharmacol Exp Ther, 2018;366(1):105-112. PMID: 29674333.
  13. [pubmed] Asai H, et al. "Reversal of hemorrhagic shock in rats using the metabolically stable thyrotropin-releasing hormone analog taltirelin hydrate." J Recept Signal Transduct Res, 2011;31(6):416-22. PMID: 22044177.
  14. [pubmed] Eto K, et al. "Taltirelin, a thyrotropin-releasing hormone analog, alleviates mechanical allodynia through activation of descending monoaminergic neurons in persistent inflammatory pain." Brain Res, 2011;1414:50-7. PMID: 21872219.
  15. [pubmed] Dougherty JP, et al. "Taltirelin alleviates fatigue-like behavior in mouse models of cancer-related fatigue." Pharmacol Res, 2017;124:1-8. PMID: 28720519.
  16. [pubmed] Ding K, et al. "Taltirelin treatment alleviates PTSD-like symptoms and restores neural oscillations in male mice receiving single prolonged stress." Neuropharmacology, 2026;284:110791. PMID: 41330489.
  17. [pubmed] Aggarwal J, et al. "Optical and pharmacological manipulation of hypoglossal motor nucleus identifies differential effects of taltirelin on sleeping tonic motor activity and responsiveness." Sci Rep, 2023;13(1):12299. PMID: 37516800.

Sources & Citations

Studies were read from their PubMed abstracts, October 3 and October 16, 2026; US and EU status from openFDA and the EMA register, October 3, 2026. A 2026 erratum to the Korean trial (PMID 41714866) is not cited separately.

Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.

Last reviewed: 2026-10-03